[go: up one dir, main page]

ES2159043T3 - Derivado carboestirilico para el tratamiento de enfermedades oculares. - Google Patents

Derivado carboestirilico para el tratamiento de enfermedades oculares.

Info

Publication number
ES2159043T3
ES2159043T3 ES96932058T ES96932058T ES2159043T3 ES 2159043 T3 ES2159043 T3 ES 2159043T3 ES 96932058 T ES96932058 T ES 96932058T ES 96932058 T ES96932058 T ES 96932058T ES 2159043 T3 ES2159043 T3 ES 2159043T3
Authority
ES
Spain
Prior art keywords
derivative
treatment
carboestirilic
eye diseases
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96932058T
Other languages
English (en)
Inventor
Hiroki Urashima
Yasuhiro Takeji
Hisashi Shinohara
Shigeki Fujisawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2159043T3 publication Critical patent/ES2159043T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION PROPORCIONA UN AGENTE PARA TRATAR ENFERMEDADES OFTALMOLOGICAS QUE CONTIENE, COMO PRINCIPIO ACTIVO, UN DERIVADO CARBOSTIRILO O UNA SAL DE ESTE DE FORMULA GENERAL (I), EN DONDE R ES UN ATOMO HALOGENO. LA INVENCION SUPONE, EN PARTICULAR, UN AGENTE EFICAZ PARA EL TRATAMIENTO DE LA XEROFTALMIA (SINDROME DEL OJO SECO).
ES96932058T 1995-10-12 1996-10-01 Derivado carboestirilico para el tratamiento de enfermedades oculares. Expired - Lifetime ES2159043T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26389695 1995-10-12
JP5733796 1996-03-14

Publications (1)

Publication Number Publication Date
ES2159043T3 true ES2159043T3 (es) 2001-09-16

Family

ID=26398366

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96932058T Expired - Lifetime ES2159043T3 (es) 1995-10-12 1996-10-01 Derivado carboestirilico para el tratamiento de enfermedades oculares.

Country Status (16)

Country Link
US (1) US6060486A (es)
EP (1) EP0859615B1 (es)
KR (1) KR100281865B1 (es)
CN (1) CN1132580C (es)
AR (3) AR004214A1 (es)
AT (1) ATE201992T1 (es)
AU (1) AU709734B2 (es)
CA (1) CA2234247C (es)
DE (1) DE69613386T2 (es)
DK (1) DK0859615T3 (es)
ES (1) ES2159043T3 (es)
GR (1) GR3036457T3 (es)
MX (1) MX9802817A (es)
PT (1) PT859615E (es)
TW (1) TW446702B (es)
WO (1) WO1997013515A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US6623754B2 (en) * 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
DE10133870A1 (de) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmisches Mittel, Verwendung von EGF zur Behandlung von Dry Eye-Syndrom und Insert zur Verabreichung von EGF am Auge
KR100907407B1 (ko) * 2002-09-28 2009-07-10 주식회사 케이티 대량 메시지 동보 전송을 위한 메시지 예약 및 전송 방법
US7879877B2 (en) 2003-07-30 2011-02-01 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives for accelerating salivation
ATE552838T1 (de) * 2003-11-14 2012-04-15 Senju Pharma Co Wässrige lösung mit aminoglykosid-antibiotikum und bromfenac
TWI340650B (en) * 2004-01-21 2011-04-21 Otsuka Pharma Co Ltd Amine saly of carbostyril derivative
WO2006022291A1 (ja) 2004-08-27 2006-03-02 Senju Pharmaceutical Co, .Ltd. ドライアイ治療用点眼液
TWI363626B (en) 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
TW200808375A (en) * 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
WO2009154304A2 (en) * 2008-06-19 2009-12-23 Otsuka Pharmaceutical Co., Ltd. A pharmaceutical composition
WO2012114317A1 (en) 2011-02-25 2012-08-30 Nuformix Limited Novel rebamipide complexes and cocrystals
TW201322982A (zh) 2011-11-01 2013-06-16 Otsuka Pharma Co Ltd 用於治療前眼疾病之藥劑，該藥劑包含瑞巴派特及眼淚保持劑
KR101692578B1 (ko) 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
AU2015252852B2 (en) * 2014-05-02 2019-03-28 Massachusetts Eye And Ear Infirmary Grading corneal fluorescein staining
KR102307958B1 (ko) 2015-10-01 2021-10-05 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
KR20170039347A (ko) 2015-10-01 2017-04-11 삼진제약주식회사 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법
JP7258778B2 (ja) 2017-03-05 2023-04-17 レスデブコ リサーチ アンド ディベロップメント カンパニー リミテッド 感染によるものではない刺激の治療のための点眼剤
KR102615076B1 (ko) 2021-07-14 2023-12-19 대우제약 주식회사 안정한 레바미피드 점안제의 대용량 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI80022C (fi) * 1982-07-05 1990-04-10 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat.
JPH0713138B2 (ja) * 1986-07-30 1995-02-15 保土谷化学工業株式会社 ポリテトラメチレンエ−テルグリコ−ルの製法
DK0543018T3 (da) * 1991-06-07 1996-02-05 Otsuka Pharma Co Ltd Antidiabetikum
TW227558B (es) * 1992-05-14 1994-08-01 Otsuka Pharma Co Ltd
CN1105799A (zh) * 1993-03-18 1995-07-26 大制药株式会社 作为基质金属蛋白酶抑制剂的喹诺酮衍生物
JP2839847B2 (ja) * 1993-10-21 1998-12-16 大塚製薬株式会社 インターロイキン−８産生抑制剤
KR970704439A (ko) * 1994-08-10 1997-09-06 오쓰카 아키히코 눈의 염증 및/또는 상처의 예방 및 치료 방법(Method of preventing and treating ophthalmic inflammation and/or wound)

Also Published As

Publication number Publication date
EP0859615B1 (en) 2001-06-13
DK0859615T3 (da) 2001-09-03
PT859615E (pt) 2001-09-28
AR070051A2 (es) 2010-03-10
DE69613386T2 (de) 2002-05-23
AU7097596A (en) 1997-04-30
TW446702B (en) 2001-07-21
AR055393A2 (es) 2007-08-22
CN1202108A (zh) 1998-12-16
US6060486A (en) 2000-05-09
KR100281865B1 (ko) 2001-02-15
WO1997013515A1 (en) 1997-04-17
MX9802817A (es) 1998-09-30
ATE201992T1 (de) 2001-06-15
GR3036457T3 (en) 2001-11-30
AR004214A1 (es) 1998-11-04
DE69613386D1 (de) 2001-07-19
AU709734B2 (en) 1999-09-02
CA2234247C (en) 2005-05-10
EP0859615A1 (en) 1998-08-26
CA2234247A1 (en) 1997-04-17
CN1132580C (zh) 2003-12-31
KR19990064187A (ko) 1999-07-26

Similar Documents

Publication Publication Date Title
ES2159043T3 (es) Derivado carboestirilico para el tratamiento de enfermedades oculares.
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
CY1115759T1 (el) Αντιβιοτικες συνθεσεις για θεραπεια του οφθαλμου
ES2059571T3 (es) Fumagilina como agente angiostatico.
BRPI0414331A (pt) método de destruição de bactéria numa área de tratamento do paciente e composição antimicrobiana de terapia fotodinámica
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
ES527494A0 (es) Procedimiento para esterilizar superficies que entraran en contacto con tejidos vivos
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
BR0015392A (pt) Lipoxina a4 e seus análogos para o tratamento de olho ressecado
EE05315B1 (et) Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
ES2131373T3 (es) Composicion oftalmica para prevenir o tratar el ojo seco o una enfermedad causada por el mismo, que comprende acido 12-sulfodeshidroabietico.
ES2183359T3 (es) Agente desinfectante de pezones por inmersion.
BR0108115A (pt) Uso de uma quantidade eficaz de pelo menos um composto de tipo retinóide como agente antibacteriano e processo de tratamento cosmético para limpar a pele ou corrigir se odor
ES2143467T3 (es) Agente terapeutico para el tratamiento de las heridas.
ES2109752T3 (es) Medicamento para tratamiento terapeutico y profilactico de enfermedades causadas por hiperplasia de las celulas de los musculos lisos.
BR9915569A (pt) Método para o tratamento de doenças neovasculares oculares
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
BR0114318A (pt) Composições de limpeza e desinfetantes para superfìcies duras
BR0017340A (pt) Tratamento de trauma e outras indicações
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas
MX9302818A (es) Agente para incrementar somatostatina o para inhibir la reduccion de somatostatina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 859615

Country of ref document: ES